This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or registerLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutAboutAntibacterialsAntifungalsAntimicrobial Resistance(AMR)Our CommitmentOur CommitmentPfizer’s Heritage in AMR
About Antibacterials

Emerging antimicrobial resistance is a global health and development threat.1 Pfizer is committed to promoting the appropriate use of antibiotics, so that they continue to fight infections when they are needed.2 Our antibacterial portfolio includes products which provide alternative therapeutic options for difficult-to-treat infections such as Methicillin Resistant Staphylococcus Aureus (MRSA) and multidrug-resistant infections that are resistant to traditional antibiotics.3-6

Prescribing Information:

Zavicefta® (Avibactam sodium, ceftazidime pentahydrate)  
 
Zinforo® (ceftaroline fosamil) 

Zyvox® (linezolid)  


Tygacil® (tigecycline) 

References:

World Health Organisation (2021, November 17). Antimicrobial Resistance. Available at Antimicrobial resistance (who.int). Last accessed September 2023.

Pfizer. Committed to the fight against Antimicrobial Resistance (AMR). Pfizer EU Policy. Available at: https://www.pfizereupolicy.eu/article/committed-fight-against-antimicrobial-resistance-amr. Last accessed September 2023.

Zavicefta. Summary of Product characteristics. 

Zinforo. Summary of Product characteristics.

Zyvox. Summary of Product Characteristics.

Tygacil. Summary of Product Characteristics.
About Anti-infectives Signs and symptoms

Clinical suspicion of haemophilia should be raised for patients with a history of easy bruising, spontaneous, or excessive bleeding following trauma or surgery.1

 Find out more Treatment options

Haemophilia management involves treating specific haemorrhages, as well as preventing bleed recurrence, limiting complications, and restoring tissue and/or organ function to a pre-bleed state.1​​​​​​​

 Find out more

Legal Category: S1A
Further information is available upon request

PP-UNP-IRL-0627 Date of preparation: September 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.